Literature DB >> 16130520

4'-Ethynylstavudine (4'-Ed4T) has potent anti-HIV-1 activity with reduced toxicity and shows a unique activity profile against drug-resistant mutants.

Hiromichi Tanaka1, Kazuhiro Haraguchi, Hiroki Kumamoto, Masanori Baba, Yung-Chi Cheng.   

Abstract

A nucleoside analogue 4'-ethynylstavudine (4'-Ed4T) was recently synthesized during chemical studies directed towards the development of a new route to 4'-carbon-substituted nucleosides. This compound was found to be more anti-HIV-1 active than the parent compound stavudine (d4T) and much less toxic to various cells and also to mitochondrial DNA synthesis. It became apparent that 4'-Ed4T is a better substrate for human thymidine kinase than d4T, and very much more resistant to catabolism by thymidine phosphorylase. The study of 4'-Ed4T against various drug-resistant HIV-1 mutants has disclosed its unique activity profile.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16130520     DOI: 10.1177/095632020501600402

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  6 in total

1.  In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

Authors:  Zhufang Li; Brian Terry; William Olds; Tricia Protack; Carol Deminie; Beatrice Minassian; Beata Nowicka-Sans; Yongnian Sun; Ira Dicker; Carey Hwang; Max Lataillade; George J Hanna; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

Review 2.  From the chemistry of epoxy-sugar nucleosides to the discovery of anti-HIV agent 4'-ethynylstavudine-Festinavir.

Authors:  Kazuhiro Haraguchi; Shingo Takeda; Yutaka Kubota; Hiroki Kumamoto; Hiromichi Tanaka; Takayuki Hamasaki; Masanori Baba; Elijah Paintsil; Yung-Chi Cheng
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

3.  The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Sally S Leong; Kate M Parker; Mariah K Oakes; Papa Salif Sow; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

4.  Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.

Authors:  Christal D Sohl; Rajesh Kasiviswanathan; Jiae Kim; Ugo Pradere; Raymond F Schinazi; William C Copeland; Hiroaki Mitsuya; Masanori Baba; Karen S Anderson
Journal:  Mol Pharmacol       Date:  2012-04-18       Impact factor: 4.436

5.  Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.

Authors:  Eleftherios Michailidis; Bruno Marchand; Eiichi N Kodama; Kamlendra Singh; Masao Matsuoka; Karen A Kirby; Emily M Ryan; Ali M Sawani; Eva Nagy; Noriyuki Ashida; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

Review 6.  Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.

Authors:  Stefan G Sarafianos; Bruno Marchand; Kalyan Das; Daniel M Himmel; Michael A Parniak; Stephen H Hughes; Eddy Arnold
Journal:  J Mol Biol       Date:  2008-11-03       Impact factor: 5.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.